Patents Assigned to Apex Bioscience, Inc.
-
Patent number: 7038016Abstract: The present invention employs a dissolved activated polyethylene glycol (aPEG) or related molecule that has been passed through a filtration means for the substantial reduction of bioburden or endotoxin levels in the aPEG solution. The resulting filtered aPEG solution can be used for the preparation of a PEGylated hemoglobin solution containing substantially reduced levels of bioburden or endotoxin.Type: GrantFiled: August 21, 2001Date of Patent: May 2, 2006Assignee: Apex Bioscience, Inc.Inventors: Todd Lewis Talarico, Cyrus John Stacey
-
Patent number: 6747132Abstract: The present invention employs a filtration step during the hemoglobin purification process that substantially decreases viral contamination of a hemoglobin solution. The filtration means can be used to separate hemoglobin and several endogenous antioxidant enzymes from red blood cell stroma and potential adventitious agents. The purified hemoglobin/antioxidant composition is then subjected to a chemical modification process. The resulting modified hemoglobin/antioxidant composition is then fractionated to remove unmodified hemoglobin species and residual reactants, formulated in electrolytes and rendered sterile. The resulting modified hemoglobin product is substantially free of viral contamination and contains at least one endogenous antioxidant enzyme that retains antioxidant activity.Type: GrantFiled: August 16, 2001Date of Patent: June 8, 2004Assignee: Apex Biosciences, Inc.Inventors: Christopher Thomas Privalle, Cyrus John Stacey, Todd Lewis Talarico
-
Publication number: 20030045602Abstract: The present invention employs a dissolved activated polyethylene glycol (aPEG) or related molecule that has been passed through a filtration means for the substantial reduction of bioburden or endotoxin levels in the aPEG solution. The resulting filtered aPEG solution can be used for the preparation of a PEGylated hemoglobin solution containing substantially reduced levels of bioburden or endotoxin.Type: ApplicationFiled: August 21, 2001Publication date: March 6, 2003Applicant: Apex Bioscience, Inc.Inventors: Todd Lewis Talarico, Cyrus John Stacey
-
Patent number: 6350729Abstract: The invention is directed to a method for the prophylaxis or treatment of an animal for deleterious physiological effects such as systemic hypotension caused by nitric oxide production induced by a biological response modifier. Examples of such biological response modifiers include but are not limited to a cytokine and an endotoxin. The invention is also directed to a method for the treatment of septic shock.Type: GrantFiled: July 13, 2000Date of Patent: February 26, 2002Assignees: Board of Regents, The University of Texas System, Apex Bioscience, Inc., Duke UniversityInventors: Robert G. Kilbourn, Joseph De Angelo, Joseph Bonaventura
-
Patent number: 6172039Abstract: The invention is directed to a substantially pure mammalian globin chain or heme-binding fragment thereof. The invention is further directed to recombinant DNA vectors capable of expressing at least one globin chain or substantially homologous variant thereof in yeast. The invention also relates to methods for expressing at least one globin chain or substantially homologous variant thereof in yeast. Expressed alpha-like globin and beta-like globin chains or variants thereof may be combined with a source of heme to produce hemoglobin or a substantially homologous variant thereof. Additionally, expressed gamma-globin chains may be combined with a source of heme to produce hemoglobin or a substantially homologous variant thereof. The invention also relates to methods for expressing hemoglobin or variants thereof in yeast where the heme is produced by the yeast and ligated to globins to form hemoglobin in vivo.Type: GrantFiled: June 5, 1995Date of Patent: January 9, 2001Assignee: Apex Bioscience, Inc.Inventors: Joseph De Angelo, Nalini M. Motwani, Wajeeh Bajwa, Joseph Bonaventura
-
Patent number: 6103690Abstract: The invention is directed to a method for the prophylaxis or treatment of an animal for deleterious physiological effects such as systemic hypotension caused by nitric oxide production induced by a biological response modifier. Examples of such biological response modifiers include but are not limited to a cytokine and an endotoxin. The invention is also directed to a method for the treatment of septic shock.Type: GrantFiled: December 2, 1998Date of Patent: August 15, 2000Assignees: Board of Regents, The University of Texas System, Apex BioScience, Inc., Duke UniversityInventors: Robert G. Kilbourn, Joseph De Angelo, Joseph Bonaventura
-
Patent number: 6020308Abstract: The present invention is directed to the use of an inhibitor of NO activity, such as a nitric oxide scavenger or an NO synthase inhibitor, as as an adjunct to treatment of inappropriate tissue vascularization disorders.Type: GrantFiled: July 31, 1998Date of Patent: February 1, 2000Assignees: Duke University, North Carolina State University, Apex Bioscience, Inc.Inventors: Mark W. Dewhirst, Robert E. Meyer, Joseph Bonaventura, Joseph DeAngelo
-
Patent number: 5900403Abstract: The invention is directed to a method for the prophylaxis or treatment of an animal for deleterious physiological effects such as systemic hypotension caused by nitric oxide production induced by a biological response modifier. Examples of such biological response modifiers include but are not limited to a cytokine and an endotoxin. The invention is also direction to a method for the treatment of septic shock.Type: GrantFiled: October 2, 1997Date of Patent: May 4, 1999Assignees: Board of Regents, The University of Texas System, Duke University, Apex Bioscience, Inc.Inventors: Robert G. Kilbourn, Joseph De Angelo, Joseph Bonaventura
-
Patent number: 5827693Abstract: The invention is directed to a substantially pure mammalian globin chain or heme-binding fragment thereof. The invention is further directed to recombinant DNA vectors capable of expressing at least one globin chain or substantially homologous variant thereof in yeast. The invention also relates to methods for expressing at least one globin chain or substantially homologous variant thereof in yeast. Expressed alpha-like globin and beta-like globin chains or variants thereof may be combined with a source of heme to produce hemoglobin or a substantially homologous variant thereof. Additionally, expressed gamma-globin chains may be combined with a source of heme to produce hemoglobin or a substantially homologous variant thereof. The invention also relates to methods for expressing hemoglobin or variants thereof in yeast where the heme is produced by the yeast and ligated to globins to form hemoglobin in vivo.Type: GrantFiled: June 7, 1995Date of Patent: October 27, 1998Assignee: Apex Bioscience, Inc.Inventors: Joseph De Angelo, Nalini M. Motwani, Wajeeh Bajwa, Joseph Bonaventura
-
Patent number: 5788958Abstract: The present invention is directed to the use of an inhibitor of NO activity, such as a nitric oxide scavenger or an NO synthase inhibitor, as an antitumor therapy to reduce tumor blood flow and oxygenation. The invention is also directed to administration of a nitric oxide scavenger or a nitric oxide synthase inhibitor to enhance the effectiveness of tumor therapy with hypoxic or acidic chemotherapeutic agents or hyperthermia. The invention is also directed to the administration of a nitric oxide synthase substrate to a subject previously administered a nitric oxide synthase inhibitor, in order to selectively inhibit tumor perfusion. In a specific example, administration of cell free hemoglobin, a nitric oxide scavenger, in conjunction with mitomycin C, a hypoxic cytotoxin, results in a significant delay in tumor growth of a human tumor xenograft in a mouse compared to mitomycin C alone.Type: GrantFiled: September 6, 1996Date of Patent: August 4, 1998Assignees: Duke University, Apex Bioscience, Inc., North Carolina State UniversityInventors: Mark W. Dewhirst, Robert E. Meyer, Joseph Bonaventura, Joseph DeAngelo
-
Patent number: 5674836Abstract: The invention is directed to a method for the prophylaxis or treatment of an animal for deleterious physiological effects such as systemic hypotension caused by nitric oxide production induced by a biological response modifier. Examples of such biological response modifiers include but are not limited to a cytokine and an endotoxin. The invention is also directed to a method for the treatment of septic shock.Type: GrantFiled: January 18, 1994Date of Patent: October 7, 1997Assignees: Board of Regents, The University of Texas System, Duke University, Apex Bioscience, Inc.Inventors: Robert G. Kilbourn, Joseph De Angelo, Joseph Bonaventura
-
Patent number: 5612310Abstract: The present invention is directed to administration of a nitric oxide scavenger or a nitric oxide synthase inhibitor to enhance the effectiveness of tumor therapy with hypoxic or acidic chemotherapeutic agents or hyperthermia. In a specific example, administration of cell free hemoglobin, a nitric oxide scavenger, in conjunction with mitomycin C, a hypoxic cytotoxin, results in a significant delay in tumor growth of a human tumor xenograft in a mouse compared to mitomycin C alone.Type: GrantFiled: May 24, 1993Date of Patent: March 18, 1997Assignees: Duke University, North Carolina State University, Apex Bioscience, Inc.Inventors: Mark W. Dewhirst, Robert E. Meyer, Joseph Bonaventura, Joseph DeAngelo
-
Patent number: 5554638Abstract: The present invention is directed to the use of an inhibitor of NO activity, such as a nitric oxide scavenger or an NO synthase inhibitor, as an antitumor therapy to reduce tumor blood flow and oxygenation. The invention is also directed to administration of a nitric oxide scavenger or a nitric oxide synthase inhibitor to enhance the effectiveness of tumor therapy with hypoxic or acidic chemotherapeutic agents or hyperthermia. The invention is also directed to the administration of a nitric oxide synthase substrate to a subject previously administered a nitric oxide synthase inhibitor, in order to selectively inhibit tumor perfusion. In a specific example, administration of cell free hemoglobin, a nitric oxide scavenger, in conjunction with mitomycin C, a hypoxic cytotoxin, results in a significant delay in tumor growth of a human tumor xenograft in a mouse compared to mitomycin C alone.Type: GrantFiled: May 20, 1994Date of Patent: September 10, 1996Assignees: Duke University, Apex Bioscience, Inc., North Carolina State UniversityInventors: Mark W. Dewhirst, Robert E. Meyer, Joseph Bonaventura, Joseph DeAngelo
-
Patent number: 5480866Abstract: The invention is directed to a method for the prophylaxis or treatment of an animal for deleterious physiological effects such as systemic hypotension caused by nitric oxide production induced by a biological response modifier. Examples of such biological response modifiers include but are not limited to a cytokine and an endotoxin. The invention is also directed to a method for the treatment of septic shock. Hemoproteins such as hemoglobin, myoglobin, hemalbumin and methemalbumin, for example, are useful when administered to a hypotensive patient.Type: GrantFiled: January 18, 1994Date of Patent: January 2, 1996Assignees: Duke University, Apex Bioscience, Inc., Board of Regents, The University of Texas SystemInventors: Joseph Bonaventura, Joseph DeAngelo, Robert G. Kilbourn